The Cystic Fibrosis Foundation announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for…
The Cystic Fibrosis Foundation reported today that key indicators of health for people with cystic fibrosis - including lung function and nutritional status - are rising nationwide…